| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in IONS over the last quarter tilts toward selling: insiders offloaded a net 1,410 shares worth roughly $61K. In the past 30 days, 0 insiders bought and 2 sold.
Both insiders who sold still hold shares after their sales.
Counted by filing, the last 12 months brought 1 open-market purchase by 1 insider worth about $1.1M and 67 sales by 19 insiders worth about $124.0M. The 12 months before that brought 2 open-market purchases by 1 insider worth about $659K and 71 sales by 16 insiders worth about $74.7M.
42 of the 67 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
The largest open-market purchase in the last two years was 20,000 shares by Michael R Hayden (Director) at an average $52.94 on July 31, 2026, about $1.1M. Three months later IONS was down 14%.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 242.8K | $9.81M | - | |
| Dir | 161.2K | $6.52M | - | |
| VP | 102.9K | $4.16M | - | |
| CFO | 82.7K | $3.34M | - | |
| VP | 77.1K | $3.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Shannon L. Devers64 | EVP, Chief Human Resources Ofc | Sale+OE | 1,357 | $43.54 | $59,081.88 | -7.1% | - | - | |
| Oct 16, 2026 | Eric Swayze67 | EVP Research | Sale+OE | 53 | $43.54 | $2,307.56 | -12.0% | - | - | |
| Jul 31, 2026 | Michael R Hayden59 | Director | Buy | 20,000 | $52.94 | $1,058,700.00 | +500.0% | -14.3% | - | |
| Jul 7, 2026 | Allene M. Diaz45 | Director | Sale+OE10b5-1 | 10,111 | $85.42 | $863,637.13 | -72.6% | -49.6% | - | |
| Jul 7, 2026 | Holly B. Kordasiewicz60 | EVP, Chief Development Officer | Sell10b5-1 | 362 | $84.30 | $30,516.60 | -1.6% | -49.6% | - | |
| Jul 7, 2026 | C Frank Bennett64 | EVP, Chief Scientific Officer | Sell10b5-1 | 20,536 | $84.95 | $1,744,623.34 | -100% | -49.6% | - | |
| Jul 1, 2026 | Joseph Klein III62 | Director | Sale+OE10b5-1 | 11,518 | $79.04 | $910,416.46 | -51.1% | -42.1% | - | |
| Jun 26, 2026 | Joseph Baroldi65 | EVP, Chief Business Officer | Sale+OE10b5-1 | 5,635 | $80.16 | $451,698.78 | -54.7% | -46.0% | - | |
| Jun 26, 2026 | Patrick R. O'Neil63 | EVP CLO & General Counsel | Sell10b5-1 | 3,069 | $80.00 | $245,520.00 | -4.8% | -46.0% | - | |
| Jun 26, 2026 | Eugene Schneider63 | EVP, Chf Clinical Develop Officer | Sale+OE10b5-1 | 26,000 | $81.05 | $2,107,196.00 | -25.2% | -46.0% | - |